2021年11月，在伦敦Royal Marsden医院，HMBD-001进行了首次人体输注，距新加坡的Hummingbird Bioscience约7,000英里（11,265公里）。这家临床期公司已筹集超过1.5亿美元，并多年致力于设计能阻断致病讯号的抗体，随后改用ADC方法将药物送至病灶组织，同时降低对健康细胞的暴露。其对患者的核心假设很清楚：抗体应抑制HER3功能与讯号，而不仅是结合HER3。HER3在30年前即被鉴定，与生长、增殖与耐药相关，但由于肿瘤可透过多种路径活化并适应，转化始终困难。

新加坡的生态系使进展更快。SG100K测序已从100,000个基因组识别超过9,800万个变异，其中超过一半此前未被发现。在少于600万人口、面积280平方英里（725平方公里）的国家，超过30家初创企业已达十亿美元估值，且研究、临床与制造节点彼此接近。Hummingbird得以在单一体系中迭代计算假说、机制实验和研发，并借由国家项目及SGGC的资金与伙伴支持，从实验室决策快速转入执行。

HMBD-001的早期评估将安全性、耐受性与决策级资料优先，涵盖多种癌症。积极讯号支持从伦敦扩展到国际站点。1月，Ingram宣布HMBD-501剂量已开始，且该试验正在美国与澳洲招募。更广泛的入组将检测疗效模式并改善患者筛选。2025年3月，Ingram与Jerome Boyd-Kirkup在新加坡和西雅图成立Callio Therapeutics，开发双有效荷载ADC，这是一个单一抗体平台，可承载两种药物并作用于多个肿瘤脆弱点，将Hummingbird的HER3计划延伸并将类似概念应用于自身免疫病管线。从首次输注到该衍生公司成立的路径，展示了从新加坡的分子假说到全球患者导向临床的可扩展模型。

In November 2021, at London’s Royal Marsden hospital, HMBD-001 made its first human infusions, about 7,000 miles (11,265 km) from Hummingbird Bioscience in Singapore. The clinical-stage company had raised more than $150 million and had spent years on antibodies that block disease-driving signals, then ADC approaches to send drugs to diseased tissue while reducing healthy-cell exposure. Its hypothesis in patients was clear: an antibody should suppress HER3 function and signaling, not merely bind it. HER3—identified over 30 years ago and linked to growth, proliferation, and resistance—has long resisted translation because tumors can activate and adapt through many pathways.

Singapore’s ecosystem enabled speed. SG100K sequencing already identified over 98 million variants from 100,000 genomes, with over half previously unknown. In fewer than six million people on 280 square miles (725 km²), more than 30 startups have reached billion-dollar valuations, and research, clinical, and manufacturing nodes are close. Hummingbird could iterate computational hypotheses, mechanistic experiments, and development in one system and then move from lab decisions to execution with national programs and SGGC capital-plus-partner support.

Early HMBD-001 evaluations prioritized safety, tolerability, and decision-grade datasets across multiple cancers. Encouraging signals supported expansion from London to international sites. In January, Ingram announced that HMBD-501 dosing had started, and that trial is now recruiting in the United States and Australia. Broader enrollment will test efficacy patterns and improve patient selection. In March 2025, Ingram and Jerome Boyd-Kirkup launched Callio Therapeutics in Singapore and Seattle to develop dual-payload ADCs, a single-antibody platform for two drugs and multiple tumor vulnerabilities, extending Hummingbird’s HER3 program and applying similar concepts to autoimmune disease pipelines. The path from first infusion to this spinout illustrates a scalable model from molecular hypotheses in Singapore to global patient-facing trials.